JNJ-75276617 (Bleximenib, Menin-MLL inhibitor 24) is an orally bioavailable, potent inhibitor of menin targeting the menin-KMT2A selective protein-protein interaction. It also acts as an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL). JNJ-75276617 displays highly potent antiproliferative activity across several acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cell lines and patient samples.

Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively.

1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide (BMIM TFSI) is a room-temperature ionic liquid with excellent ionic conductivity. Its solvation dynamics and conductivity are affected by proton concentration, which influences its performance in electrochemical applications.

1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide (BMIM TFSI) is a room-temperature ionic liquid with excellent ionic conductivity. Its solvation dynamics and conductivity are affected by proton concentration, which influences its performance in electrochemical applications.

(S)-Flurbiprofen (Esflurbiprofen), an active enantiomer of Flurbiprofen, acts as an inhibitor of cyclooxygenase (COX-2) with an IC50 value of 0.48 μM, respectively. It also helps in the significant reduction of the inflammatory mediator-induced CGRP release.

(S)-Flurbiprofen (Esflurbiprofen), an active enantiomer of Flurbiprofen, acts as an inhibitor of cyclooxygenase (COX-2) with an IC50 value of 0.48 μM, respectively. It also helps in the significant reduction of the inflammatory mediator-induced CGRP release.

(S)-Flurbiprofen (Esflurbiprofen), an active enantiomer of Flurbiprofen, acts as an inhibitor of cyclooxygenase (COX-2) with an IC50 value of 0.48 μM, respectively. It also helps in the significant reduction of the inflammatory mediator-induced CGRP release.

(S)-Flurbiprofen (Esflurbiprofen), an active enantiomer of Flurbiprofen, acts as an inhibitor of cyclooxygenase (COX-2) with an IC50 value of 0.48 μM, respectively. It also helps in the significant reduction of the inflammatory mediator-induced CGRP release.

Mirodenafil (SK3530) is a second-generation, highly selective inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.34 nM, primarily used in the treatment of erectile dysfunction (ED).

Mirodenafil (SK3530) is a second-generation, highly selective inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.34 nM, primarily used in the treatment of erectile dysfunction (ED).